Global Oral Solid Dosage Contract Manufacturing Market – Sales, Revenue and Market Share Analysis 2022 to 2032

According to the latest industry analysis by Persistence Market Research, the global oral solid dosage contract manufacturing market recorded sales worth US$23.4 billion in 2021 and is expected to grow at a CAGR of 5.9% from 2022 to 2032.

Contract research organizations are outsourced companies that support pharmaceutical and biotechnology companies in their clinical and preclinical studies on a contractual basis. Manufacturing costs are increasing day by day. As a result, large and small pharmaceutical and biotech companies are focusing their efforts on CDMOs to secure long-term contract manufacturing agreements. This will help companies to stick to fixed manufacturing rates and CDMOs to improve manufacturing quality.

Tablets and capsules are the basic types of solid dosage forms. Companies today are using new technologies to increase the bioavailability of dosage forms to increase patient compliance. Contract manufacturers of oral solid dosage forms introduce new products or upgrade older products. For example, many patients, especially pediatric patients, have difficulty swallowing tablets. Therefore, time-release beads can help optimize the release rate. Companies also make sublingual tablets for quick medication.

Get Free Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/25768

The increasing complexity of new drug molecules will drive the market growth as CROs and CDMOs provide manufacturing with expertise to help manage the complexity of new molecules. Over the next few years, the development and contract manufacturing industry will be boosted by increased investment in infrastructure development and plant expansion, as well as CDMO’s capabilities to provide fully integrated services.

Since the oral solid dosage contract manufacturing market is consolidated with few key players, it presents many lucrative opportunities for new entrants to gain a foothold in this industry. The increase in strategic collaborations can also prove to be a beneficial factor for market players to expand their footprint.

Company Profiles:

  • Recipharm AB
  • AbbVie
  • Patheon NV (ThermoFisher Scientific)
  • Catalent Inc.
  • NextPharma
  • Capsugel (Lonza Group SA)
  • Aurobindo Pharma Limited
  • Siegfried AG
  • Piramal pharmaceutical solutions
  • Corden Pharma
  • Kremoint Pharma Pvt Ltd.
  • HERMES PHARMA Ltd
  • Medipaams India Private Limited
  • Alpex Pharma
  • Abaris Healthcare Pvt Ltd
  • Ardena Holdings S.A.
  • Aphena Pharma Solutions
  • Actiza Pharmaceutical Private Limited
  • Sunwin Healthcare PVT. LTD
  • Saffron Medicare PVT. LTD
  • Kosher Pharmaceuticals
  • Dr. Reddy’s Laboratory
  • GlaxoSmithKline Plc
  • Boehringer Ingelheim BioXcellence
  • Aenova Holding

Methodology Request @ https://www.persistencemarketresearch.com/methodology/25768

Key insights from market research

  • The galenic form of tablets accounted for 34% market share in 2021.
  • Pharmaceutical product development held around half of the overall market share, by value, in 2021.
  • The immediate release mechanism has a market share of 53.7%.
  • The limited availability of resources and the increased focus on reducing R&D and operational costs are the main reasons why small and medium-sized pharmaceutical or biotechnology companies are opting for outsourcing. As such, these companies dominate the end-user segment and captured around 32% market share in 2021.
  • The North American contract manufacturing market for solid oral doses accounted for 25.2% of the global market share.

“Rising strategic collaborations between pharma giants and emerging players will drive the demand for contract manufacturing of oral solid doses over the coming years,” says an analyst from Persistence Market Research.

Market competition:

Leading oral solid dosage contract manufacturing vendors are investing in R&D activities to develop new technologies for the development of solid dosage formulations. Along with R&D investments, major players are also aiming for various expansions to create goodwill and successfully establish their presence in the global market.

  • In January 2022, Lonza, Forbion and BioGeneration Ventures extended their collaboration to include small molecule development and manufacturing services.

What does the report cover?

Persistence Market Research offers a unique perspective and actionable insights into the Oral Solid Dosage Contract Manufacturing Market in its latest study, presenting a historical demand assessment from 2017 to 2021 and projections for 2022 to 2032.

The research study is based on the dosage form (tablets {conventional release, modified release, chewable tablets, effervescent tablets}, capsules {hard gelatin capsules, soft gelatin} capsules/capsules; powders and granules; lozenges and lozenges; gums), mechanism (immediate release; delayed release; controlled release), application (pharmaceutical product development; manufacture of fillers and finishes; packaging/labelling; others) and end user (large pharmaceutical/biotech companies; small and medium pharmaceutical/biotechnology companies; emerging/virtual pharmaceutical companies; nutraceutical companies), in seven key regions of the world.

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York, NY 10007 USA
Telephone in the United States – +1-646-568-7751
USA-Canada Toll Free – +1 800-961-0353
Sales[email protected]

Comments are closed.